Francis deSouza, Illumina CEO (Photographer: Kyle Grillot/Bloomberg via Getty Images)
February 8, 2023 09:22 AM ESTUpdated 09:40 AM
Pharma

Af­ter a bad quar­ter, Il­lu­mi­na fo­cus­es on new DNA se­quenc­ing plat­form

Jared Whitlock

Features Editor

Il­lu­mi­na on Tues­day re­port­ed a steep drop in quar­ter­ly rev­enue and in 2022, the com­pa­ny took a charge of $3.91 bil­lion to write down the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times